In contrast, overexpression of Nrf2 in astrocytes is protective in models of Parkinson’s disease [20,24], amyotrophic lateral sclerosis [18], Huntington’s disease [206,211], and multiple sclerosis [228], indicating that activation of Nrf2 in astrocytes is a viable therapeutic target for these diseases. Here, NFE2L2 is linked to Parkinson disease.